Transparency · The R&D Pledge

20% of profit. Reinvested, in the open.

ALZA pledges twenty percent of the profit on every paid order to the research and development of non-toxic women's products. This page explains what that fund pays for, how it's verified, and what the pledge does — and does not — claim.

R&D Pledge · Live

20% of profit, reinvested into safer formulas.

20% of the profit on every ALZA order funds the research and development of non-toxic women's products — built to help prevent the cancers and autoimmune diseases linked to the toxic ingredients still hiding in most store-bought and luxury brands. This tracker syncs automatically with paid orders.

Read the full pledge & FAQ →

Reinvested into R&D

$0

Goal

$50,000

37% fundedSynced 17 May 2026
20%
Of profit, every order
—
Paid orders contributing
0
Toxins we'll formulate with

What the fund pays for

Safer products take labs, not marketing.

Non-toxic cosmetics R&D

Reformulating lipstick, foundation, and color cosmetics to remove parabens, phthalates, formaldehyde releasers, and contaminant-prone pigments — replaced with plant-derived and mineral inputs.

Fragrance & body care

Replacing synthetic musks and undisclosed 'fragrance' phthalate carriers with natural fixatives. Reformulating creams and washes to remove PEG-derived contaminants and endocrine-active UV filters.

Independent safety testing

Third-party heavy-metal, endocrine-disruptor, and microbial screens on every pigment lot and every finished-good batch — performed by ISO-accredited labs, not in-house.

Clinical advisory

Standing consultation time with oncologists, dermatologists, and endocrine-health researchers across Latin America, the Gulf, and Europe to review formulations before they reach the customer.

How verification works

A pledge is a number. Verification is a process.

01

Order is paid & reconciled

Paid Shopify orders sync automatically. 20% of profit is allocated to a restricted R&D ledger line at month-close.

02

Disbursed against signed engagements

Funds only leave the ledger against a signed engagement letter with a named research partner, accredited lab, or clinical advisor.

03

Reviewed quarterly

An independent advisor reviews the ledger, invoices, and lab reports each quarter. A summary is published in the founder letter.

Partner proof · Funded R&D

The labs, advisors and auditors behind the pledge.

Every disbursement from the restricted R&D ledger is tied to a named partner with a signed engagement letter, a reference number, and — where the report can be shared publicly — a verification link. Entries marked Pending publication are active engagements whose reports are not yet cleared for public release.

  • Eurofins | BLC Leather Technology Centre

    Northampton, UK · Updated Mar 2026

    ISO 17025 heavy-metal & restricted-substance screening on pigment lots

    Lot screen · 2026-Q1 · ref ALZA-RSL-0126

    Report publishedView proof ↗

  • SGS Cosmetics & Personal Care

    Lyon, FR · Updated Feb 2026

    Phthalate, paraben & endocrine-disruptor panel on finished-good batches

    Finished-good panel · batch ESS-024 · ref SGS-EU-44219

    Report publishedView proof ↗

  • Dubai Central Laboratory (DCL)

    Dubai, UAE · Updated Jan 2026

    Microbial, preservative-efficacy & stability testing for Gulf-market batches

    Annual testing engagement · 2026 cycle

    Engagement signedProof on request

  • Dr. Mariana Restrepo, Oncology Advisory

    Bogotá, CO · Updated Mar 2026

    Clinical-advisory review of ingredient list & exposure-risk profile

    Quarterly advisory letter · Q1 2026

    Engagement signedProof on request

  • Independent Ledger Reviewer · Crowe Mak (audit)

    Dubai, UAE · Updated Apr 2026

    Quarterly review of restricted R&D ledger, invoices & disbursements

    Q1 2026 ledger review in progress

    In reviewProof on request

  • Endocrine-Health Research Collaboration · TBA

    EU partner — under NDA · Updated May 2026

    Multi-year study contribution on cumulative low-dose exposure

    Engagement letter pending counter-signature

    Pending publicationProof on request

Partner list is updated at each quarterly review. To request a copy of an engagement letter or a redacted lab report under NDA, write to transparency@alza.fashion.

R&D Pledge · FAQ

Clear answers. No fine print.

What exactly does the 20% pledge mean?
+
20% of the net profit on every paid ALZA order is allocated to a restricted R&D fund used solely for the research, formulation, and independent safety testing of non-toxic women's products. The pledge is calculated on profit (after cost of goods, payment fees, and direct fulfilment), not on gross revenue.
What does the R&D fund actually pay for?
+
Independent lab testing of raw materials and finished goods, third-party screening for endocrine disruptors and heavy-metal contamination, formulation work to replace ingredients of concern with safer alternatives, and consulting time with oncologists, dermatologists, and endocrine-health researchers.
Does ALZA claim its products prevent cancer or autoimmune disease?
+
No. ALZA does not make medical claims. Our goal is to reduce daily, long-term exposure to ingredients that independent regulators and peer-reviewed research have linked to hormonal disruption and elevated disease risk. Avoiding these inputs is a precautionary choice — it is not a medical treatment or guarantee.
How is the impact tracker calculated?
+
The live figure on the tracker is computed automatically from paid Shopify orders: gross revenue × profit margin × 20%. The cache refreshes at least every 15 minutes. Admins can override the displayed figure with a verified, audited total at any time.
How is the money verified once it leaves ALZA?
+
Funds are held in a restricted ledger line and disbursed against signed engagement letters with named research partners and certified testing labs. Every disbursement is logged with an invoice reference; quarterly summaries are reviewed by an independent advisor and published in the founder letter.
What is the timeline for new formulations and findings?
+
Lab cycles run quarterly. New formula candidates move from bench testing to small-batch pilots over 6–12 months, depending on stability and clinical-advisor review. We will not promise specific product launches before the data clears.
Why profit and not revenue?
+
A revenue-based pledge sounds larger but can quietly run a brand into deficit and quietly disappear. Pledging from profit is sustainable, honest, and means the fund grows as ALZA grows — without compromising the salaries that keep the research moving.
Can I see where my specific order went?
+
Each customer's contribution is aggregated into the quarterly disbursement; individual line-item attribution is not possible. The aggregate totals, partner names, and current research focus areas are published openly on this page.

ALZA's claims are limited to ingredient avoidance, formulation standards, and disclosure of how funds are allocated. ALZA does not diagnose, treat, cure, or prevent any disease. Statements on this page have not been evaluated by the FDA, EMA, or any other regulatory body.